Dr. Faeezah Ally

Faeezah Ally is a South African clinical researcher specializing in HIV treatment and vaccine research, with a strong focus on adolescents, children, and people living with HIV. Her work is closely aligned with multinational clinical trial networks, contributing to pivotal studies published in leading infectious diseases journals.

Her research centers on long-acting antiretroviral therapies, including injectable cabotegravir and rilpivirine, evaluating safety, pharmacokinetics, acceptability, and tolerability in adolescents. She has also advanced child-friendly antiretroviral formulations and early treatment strategies in infants, strengthening evidence for optimized pediatric HIV care.

In parallel, she has played a key role in COVID-19 vaccine trials in high HIV-prevalence settings, examining immunogenicity, heterologous boosting, and safety across diverse populations. Her work integrates rigorous clinical pharmacology with public health impact, informing treatment guidelines and vaccine policy in low- and middle-income countries.